

Jinfang Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1671010/publications.pdf>

Version: 2024-02-01

45
papers

3,932
citations

182225

30
h-index

263392

45
g-index

48
all docs

48
docs citations

48
times ranked

6968
citing authors

#	ARTICLE	IF	CITATIONS
1	USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy. <i>Nature Communications</i> , 2022, 13, 1700.	5.8	45
2	Prostate-specific oncogene OTUD6A promotes prostatic tumorigenesis via deubiquitinating and stabilizing c-Myc. <i>Cell Death and Differentiation</i> , 2022, 29, 1730-1743.	5.0	18
3	LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non-small cell lung cancer. <i>Clinical and Translational Medicine</i> , 2022, 12, e792.	1.7	14
4	Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle. <i>Cell Research</i> , 2021, 31, 80-93.	5.7	51
5	Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1. <i>Cell Death and Differentiation</i> , 2021, 28, 1773-1789.	5.0	80
6	Vasoactive Intestinal Peptide Promotes Fracture Healing in Sympathectomized Mice. <i>Calcified Tissue International</i> , 2021, 109, 55-65.	1.5	16
7	Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. <i>Molecular Cell</i> , 2021, 81, 2317-2331.e6.	4.5	97
8	Inhibition of CK1 μ potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer. <i>Nature Communications</i> , 2021, 12, 5386.	5.8	22
9	Extracellular and nuclear PD-L1 in modulating cancer immunotherapy. <i>Trends in Cancer</i> , 2021, 7, 837-846.	3.8	45
10	Deubiquitinase OTUD6A promotes proliferation of cancer cells via regulating Drp1 stability and mitochondrial fission. <i>Molecular Oncology</i> , 2020, 14, 3169-3183.	2.1	22
11	Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. <i>Nature Cell Biology</i> , 2020, 22, 1064-1075.	4.6	182
12	WWP1 Gain-of-Function Inactivation of PTEN in Cancer Predisposition. <i>New England Journal of Medicine</i> , 2020, 382, 2103-2116.	13.9	49
13	Targeting SCF E3 Ligases for Cancer Therapies. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1217, 123-146.	0.8	34
14	Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway. <i>Science</i> , 2019, 364, .	6.0	194
15	SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression. <i>Developmental Cell</i> , 2019, 48, 329-344.e5.	3.1	53
16	Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function. <i>Molecular Cell</i> , 2018, 69, 279-291.e5.	4.5	138
17	Deregulated PP1 \pm phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism. <i>Nature Communications</i> , 2018, 9, 159.	5.8	39
18	Cyclin D α -CDK4 kinase destabilizes PD-L1 via cullin 3 α -SPOP to control cancer immune surveillance. <i>Nature</i> , 2018, 553, 91-95.	13.7	660

#	ARTICLE	IF	CITATIONS
19	Enhancement of bone regeneration with the accordion technique via HIF-1 α /VEGF activation in a rat distraction osteogenesis model. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2018, 12, e1268-e1276.	1.3	32
20	Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy. <i>Trends in Biochemical Sciences</i> , 2018, 43, 1014-1032.	3.7	151
21	The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function. <i>Cancer Discovery</i> , 2017, 7, 424-441.	7.7	57
22	Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function. <i>Science Signaling</i> , 2017, 10, .	1.6	52
23	Cystic fibrosis transmembrane conductance regulator mediates tenogenic differentiation of tendon-derived stem cells and tendon repair: accelerating tendon injury healing by intervening in its downstream signaling. <i>FASEB Journal</i> , 2017, 31, 3800-3815.	0.2	30
24	TRAF2 and OTUD7B govern a ubiquitin-dependent switch that regulates mTORC2 signalling. <i>Nature</i> , 2017, 545, 365-369.	13.7	136
25	MiR-503 Promotes Bone Formation in Distraction Osteogenesis through Suppressing Smurf1 Expression. <i>Scientific Reports</i> , 2017, 7, 409.	1.6	56
26	FOXP1 ^{hi} stemness controls SLBP stability during cell cycle. <i>Cell Cycle</i> , 2017, 16, 597-598.	1.3	3
27	Effect of SDF-1/Cxcr4 Signaling Antagonist AMD3100 on Bone Mineralization in Distraction Osteogenesis. <i>Calcified Tissue International</i> , 2017, 100, 641-652.	1.5	27
28	The SCF ^{TRCP} E3 ubiquitin ligase complex targets Lipin1 for ubiquitination and degradation to promote hepatic lipogenesis. <i>Science Signaling</i> , 2017, 10, .	1.6	44
29	Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. <i>Nature Medicine</i> , 2017, 23, 1063-1071.	15.2	240
30	Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation. <i>Cancer Letters</i> , 2017, 385, 207-214.	3.2	43
31	Staphylococcal enterotoxin C2 expedites bone consolidation in distraction osteogenesis. <i>Journal of Orthopaedic Research</i> , 2017, 35, 1215-1225.	1.2	21
32	Porcine brain extract promotes osteogenic differentiation of bone marrow derived mesenchymal stem cells and bone consolidation in a rat distraction osteogenesis model. <i>PLoS ONE</i> , 2017, 12, e0187362.	1.1	8
33	Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6. <i>Oncotarget</i> , 2017, 8, 47890-47901.	0.8	30
34	Systemic Administration of Allogeneic Mesenchymal Stem Cells Does Not Halt Osteoporotic Bone Loss in Ovariectomized Rats. <i>PLoS ONE</i> , 2016, 11, e0163131.	1.1	13
35	Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt. <i>Molecular Cell</i> , 2016, 62, 929-942.	4.5	87
36	Cdh1 regulates craniofacial development via APC-dependent ubiquitination and activation of Goosecoid. <i>Cell Research</i> , 2016, 26, 699-712.	5.7	25

#	ARTICLE	IF	CITATIONS
37	Human fetal mesenchymal stem cell secretome enhances bone consolidation in distraction osteogenesis. <i>Stem Cell Research and Therapy</i> , 2016, 7, 134.	2.4	63
38	pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner. <i>Science</i> , 2016, 353, 929-932.	6.0	165
39	Cdh1 inhibits WWP2-mediated ubiquitination of PTEN to suppress tumorigenesis in an APC-independent manner. <i>Cell Discovery</i> , 2016, 2, 15044.	3.1	33
40	Akt-Mediated Phosphorylation of XLF Impairs Non-Homologous End-Joining DNA Repair. <i>Molecular Cell</i> , 2015, 57, 648-661.	4.5	59
41	Targeting Cdc20 as a novel cancer therapeutic strategy. , 2015, 151, 141-151.		194
42	The E3 ligase APC/C ^{Cdh1} promotes ubiquitylation-mediated proteolysis of PAX3 to suppress melanocyte proliferation and melanoma growth. <i>Science Signaling</i> , 2015, 8, ra87.	1.6	21
43	PtdIns(3,4,5)P ₃ -Dependent Activation of the mTORC2 Kinase Complex. <i>Cancer Discovery</i> , 2015, 5, 1194-1209.	7.7	297
44	SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression. <i>Molecular Cell</i> , 2015, 59, 917-930.	4.5	172
45	Functional characterization of Anaphase Promoting Complex/Cyclosome (APC/C) E3 ubiquitin ligases in tumorigenesis. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 277-293.	3.3	64